Top

Current Oncology Reports

Published in:

Open Access 01-06-2022 | Naltrexone | Anesthesiology and Critical Care (JP Cata, Section Editor)

Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?

Authors: Amparo Belltall, Guido Mazzinari, Oscar Diaz-Cambronero, Pilar Eroles, María Pilar Argente Navarro

Published in: Current Oncology Reports | Issue 10/2022

Abstract

Purpose of Review

Antagonists of mu-opioid receptor role in cancer progression remains to be elucidated. The objective of this review was to summarize the available evidence on antagonists of mu-opioid receptor effect on tumor progression and prognosis in different types of cancers and an evaluation of the available findings on their mechanism of action.

Recent Findings

We have found studies related to methylnaltrexone (MNTX) and naltrexone (NTX) usage in cancer outcomes-related setting. We found consistent preclinical evidence of a potential action of MNTX and NTX on cancer growth and spread mediated mainly by effect on the opioid growth factor receptor (OGFr) axis, which results in depressed cell replication. However, clinical results are scarce and limited to poor-quality evidence.

Summary

Further high-quality studies are warranted to study antagonists of mu-opioid receptor role as a therapeutic option in different types of cancer, especially in patients where the classical treatment causes unacceptable side effects.

Montagna G, Gupta HV, Hannum M, Tan KS, Lee J, Scarpa JR, et al. Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer. Br J Anaesth. 2021;126(2):367–76.CrossRef

Jorand R, Biswas S, Wakefield DL, Tobin SJ, Golfetto O, Hilton K, et al. Molecular signatures of mu opioid receptor and somatostatin receptor 2 in pancreatic cancer. Mol Biol Cell. 2016;27(22):3659–72.CrossRef

Nylund G, Pettersson A, Bengtsson C, Khorram-Manesh A, Nordgren S, Delbro DS. Functional expression of μ-opioid receptors in the human colon cancer cell line, HT-29, and their localization in human colon. Dig Dis Sci. 2008;53(2):461–6.CrossRef

Zhang YF, Xu QX, Liao LD, Xu XE, Wu JY, Wu ZY, et al. Association of mu-opioid receptor expression with lymph node metastasis in esophageal squamous cell carcinoma. Dis Esophagus. 2015;28(2):196–203.CrossRef

Yao Y, Sai Y, Yong Yao R, Kun Zhuang L, Wei Qi W, Lv J, Zhou F, et al. MOR1 expression in gastric cancer: A biomarker associated with poor outcome. Clin Transl Sci. 2015;8(2):137–42.CrossRef

Chen DT, Pan JH, Chen YH, Xing W, Yan Y, Yuan YF, et al. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target. Br J Anaesth. 2019;122(6):e157–67.CrossRef

Singleton PA, Mirzapoiazova T, Hasina R, Salgia R, Moss J. Increased μ-opioid receptor expression in metastatic lung cancer. Br J Anaesth. 2014;113(SUPPL. 1):103–8.CrossRef

Zylla D, Gourley BL, Vang D, Jackson S, Boatman S, Lindgren B, et al. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer. 2013;119(23):4103–10.CrossRef

Zhang H, Sun M, Zhou D, Gorur A, Sun Z, Zeng W, et al. Increased mu-opioid receptor expression is associated with reduced disease-free and overall survival in laryngeal squamous cell carcinoma. Br J Anaesth. 2020;125(5):722–9.CrossRef

10.

Díaz-Cambronero O, Mazzinari G, Giner F, Belltall A, Ruiz-Boluda L, Marqués-Marí A, et al. Mu opioid receptor 1 (MOR-1) expression in colorectal cancer and oncological long-term outcomes: a five-year retrospective longitudinal cohort study. Cancers (Basel). 2020;12(1):134. https://doi.org/10.3390/cancers12010134.

11.

Singleton PA, Moss J, Karp DD, Atkins JT, Janku F. The mu opioid receptor: A new target for cancer therapy? Cancer. 2015 Aug 15;121(16):2681–8. https://doi.org/10.1002/cncr.29460. Epub 2015 Jun 4. PMID: 26043235. The authors present preclinical and clinical data that support their hypothesis that the mu opioid receptor is a potential target for cancer therapy because of its plausible role in tumor progression. The authors also propose the hypothesis that PAMORAs can be used to target the mu opioid receptor.

12.

Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res. 2006;72(1–2):3–11. https://doi.org/10.1016/j.mvr.2006.04.004.CrossRefPubMed

13.

Afsharimani B, Doornebal CW, Cabot PJ, Hollmann MW, Parat MO. Comparison and analysis of the animal models used to study the effect of morphine on tumour growth and metastasis. Br J Pharmacol. 2015;172(2):251–9. https://doi.org/10.1111/bph.12589.CrossRefPubMed

14.

Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat Rev Clin Oncol. 2015;12(4):213–26. https://doi.org/10.1038/nrclinonc.2014.224.CrossRefPubMedPubMedCentral

15.

Sekandarzad MW, van Zundert AAJ, Lirk PB, Doornebal CW, Hollmann MW. Perioperative Anesthesia Care and Tumor Progression. Anesth Analg. 2017;124(5):1697–708. https://doi.org/10.1213/ANE.0000000000001652 (PMID: 27828796).CrossRefPubMed

16.

Moss J, Rosow CE. Development of peripheral opioid antagonists’ new insights into opioid effects. Mayo Clin Proc. 2008;83(10):1116–30. https://doi.org/10.4065/83.10.1116 (PMID: 18828971).CrossRefPubMed

17.

Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton PA. Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology. 2012;116(4):857–67. https://doi.org/10.1097/ALN.0b013e31824babe2 (PMID: 22343475).CrossRefPubMed

18.

Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S, Gerhold LM, LaRiviere PJ, Chen CT, Garcia JG, Salgia R, Moss J, Singleton PA. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg. 2011;112(3):558–67. https://doi.org/10.1213/ANE.0b013e31820568af.CrossRefPubMed

19.

Ringerike T, Pike E, Nevjar J, Klemp M. The use of naltrexone in low doses beyond the approved indication [Internet]. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2015 Apr. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 8-2015.

20.

Sato J, Tanaka R, Ishikawa H, Suzuki T, Shino M. A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting. Support Care Cancer. 2020;28(3):1083–8. https://doi.org/10.1007/s00520-019-04884-0 (Epub 2019 Jun 11 PMID: 31183560).CrossRefPubMed

21.

Kraft MD. Methylnaltrexone, a new peripherally acting mu-opioid receptor antagonist being evaluated for the treatment of postoperative ileus. Expert Opin Investig Drugs. 2008;17(9):1365–77. https://doi.org/10.1517/13543784.17.9.1365 (PMID: 18694369).CrossRefPubMed

22.

Chamie K, Golla V, Lenis AT, Lec PM, Rahman S, Viscusi ER. Peripherally Acting μ-Opioid Receptor Antagonists in the Management of Postoperative Ileus: a Clinical Review. J Gastrointest Surg. 2021 Jan;25(1):293–302. https://doi.org/10.1007/s11605-020-04671-x. Epub 2020 Aug 10. PMID: 32779081; PMCID: PMC7851096. This review discuss recent clinical trials evaluating the safety and efficacy of PAMORAs, with a focus on alvimopan and methylnaltrexone in patients with POI or postoperative OIC.

23.

Becker G, Blum HE. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. Lancet. 2009;373(9670):1198–206. https://doi.org/10.1016/S0140-6736(09)60139-2 (Epub 2009 Feb 13 PMID: 19217656).CrossRefPubMed

24.

Yu CS, Chun HK, Stambler N, Carpenito J, Schulman S, Tzanis E, Randazzo B. Safety and efficacy of methylnaltrexone in shortening the duration of postoperative ileus following segmental colectomy: results of two randomized, placebo-controlled phase 3 trials. Dis Colon Rectum. 2011;54(5):570–8. https://doi.org/10.1007/DCR.0b013e3182092bde (PMID: 21471758).CrossRefPubMed

25.

Ouyang R, Li Z, Huang S, Liu J, Huang J. Efficacy and Safety of Peripherally Acting Mu-Opioid Receptor Antagonists for the Treatment of Opioid-Induced Constipation: A Bayesian Network Meta-analysis. Pain Med. 2020;21(11):3224–32. https://doi.org/10.1093/pm/pnaa152 (PMID: 32488259).CrossRefPubMed

26.

Libran Oriol A, Cruz-Sequeiros C, Luque-Blanco A, Porta-Sales J. Peri- pheral acting mu opioid receptor antagonists in the treatment of opioid- induced constipation: review. Rev Soc Esp Dolor. 2020;27(1):37–49.

27.

Pergolizzi JV Jr, Christo PJ, LeQuang JA, Magnusson P. The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety. Drug Des Devel Ther. 2020;11(14):1009–25. https://doi.org/10.2147/DDDT.S221278.PMID:32210534;PMCID:PMC7075239.CrossRef

28.

Fernández-Montes A, de Velasco G, Aguín S, Farriols C, Guirado-Risueño M, Jerviz-Guía VG, Baeza-Nadal MV, Chicas-Sett R, Fírvida JL, García-Navalón F, Martín P, Perezagua-Marín C, Rodríguez D, Santamaría J, Saurí T, Cobo M. Insights into the Use of Peripherally Acting μ-Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice. Curr Treat Options Oncol. 2021 Feb 26;22(3):26. https://doi.org/10.1007/s11864-021-00816-5. PMID: 33635493. A panel of experts pools their clinical experience with PAMORAs in cancer patients with OIC and highlights the importance of timing and choice of therapy in achieving prompt OIC management and benefitting patients.

29.

Li Z, You Y, Griffin N, Feng J, Shan F. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy. Int Immunopharmacol. 2018;61:178–84. https://doi.org/10.1016/j.intimp.2018.05.020 (Epub 2018 Jun 7 PMID: 29885638).CrossRefPubMed

30.

Wang R, Zhang Y, Shan F. Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy. Int Immunopharmacol. 2019 Oct;75:105785. https://doi.org/10.1016/j.intimp.2019.105785. Epub 2019 Aug 9. PMID: 31404891. This review provides insight into the interactions between OGF and OGFr in the treatment of cancers.

31.

Zagon IS, Donahue R, McLaughlin PJ. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer. Exp Biol Med (Maywood). 2013;238(5):579–87. https://doi.org/10.1177/1535370213488483 (PMID: 23856908).CrossRef

32.

Buggy DJ, Freeman J, Johnson MZ, Leslie K, Riedel B, Sessler DI, Kurz A, Gottumukkala V, Short T, Pace N, Myles PS; StEP-COMPAC Group. Systematic review and consensus definitions for standardised endpoints in perioperative medicine: postoperative cancer outcomes. Br J Anaesth. 2018;121(1):38–44. https://doi.org/10.1016/j.bja.2018.03.020.CrossRef

33.

Wu Q, Chen X, Wang J, Sun P, Weng M, Chen W, Sun Z, Zhu M, Miao C. Nalmefene attenuates malignant potential in colorectal cancer cell via inhibition of opioid receptor. Acta Biochim Biophys Sin (Shanghai). 2018;50(2):156–63. https://doi.org/10.1093/abbs/gmx131 (PMID: 29267844).CrossRef

34.

Gorur A, Patiño M, Shi T, Corrales G, Takahashi H, Rangel R, Gleber-Netto FO, Pickering C, Myers JN, Cata JP. Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu-opioid receptor. J Cell Physiol. 2021;236(11):7698–710. https://doi.org/10.1002/jcp.30421 (Epub 2021 May 26 PMID: 34038587).CrossRefPubMed

35.

Liu WM, Scott KA, Dennis JL, Kaminska E, Levett AJ, Dalgleish AG. Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy. Int J Oncol. 2016;49(2):793–802. https://doi.org/10.3892/ijo.2016.3567 (Epub 2016 Jun 7 PMID: 27279602).CrossRefPubMed

36.

Qu N, Meng Y, Handley MK, Wang C, Shan F. Preclinical and clinical studies into the bioactivity of low-dose naltrexone (LDN) for oncotherapy. Int Immunopharmacol. 2021 Jul;96:107714. https://doi.org/10.1016/j.intimp.2021.107714. Epub 2021 May 11. PMID: 33989971. The authors summarize the associated studies on LDN oncotherapy to highlight the potential mechanisms and prospective clinical applications.

37.

Liubchenko K, Kordbacheh K, Khajehdehi N, Visnjevac T, Ma F, Khan JS, Storey M, Abd-Elsayed A, Visnjevac O. Naltrexone’s Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures. Adv Ther. 2021;38(2):904–24. https://doi.org/10.1007/s12325-020-01591-9 (Epub 2020 Dec 18 PMID: 33337537).CrossRefPubMed

38.

Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Exp Biol Med (Maywood). 2011;236(7):883–95. https://doi.org/10.1258/ebm.2011.011096 (Epub 2011 Jun 17 PMID: 21685240).CrossRef

39.

Donahue RN, McLaughlin PJ, Zagon IS. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Gynecol Oncol. 2011;122(2):382–8. https://doi.org/10.1016/j.ygyno.2011.04.009 (Epub 2011 Apr 30 PMID: 21531450).CrossRefPubMed

40.

Murugan S, Rousseau B, Sarkar DK. Beta 2 Adrenergic Receptor Antagonist Propranolol and Opioidergic Receptor Antagonist Naltrexone Produce Synergistic Effects on Breast Cancer Growth Prevention by Acting on Cancer Cells and Immune Environment in a Preclinical Model of Breast Cancer. Cancers (Basel). 2021;13(19):4858. https://doi.org/10.3390/cancers13194858.CrossRef

41.

Singleton PA, Garcia JG, Moss J. Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis. Mol Cancer Ther. 2008;7(6):1669–79. https://doi.org/10.1158/1535-7163.MCT-07-2217 (PMID: 18566238).CrossRefPubMed

42.

Singleton PA, Mambetsariev N, Lennon FE, Mathew B, Siegler JH, Moreno-Vinasco L, Salgia R, Moss J, Garcia JG. Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors. J Angiogenes Res. 2010;2(1):5. https://doi.org/10.1186/2040-2384-2-5.PMID:20298531;PMCID:PMC2831839.CrossRefPubMedPubMedCentral

43.

Singleton PA, Moreno-Vinasco L, Sammani S, Wanderling SL, Moss J, Garcia JG. Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. Am J Respir Cell Mol Biol. 2007;37(2):222–31. https://doi.org/10.1165/rcmb.2006-0327OC (Epub 2007 Mar 29 PMID: 17395891).CrossRefPubMed

44.

Wang CZ, Li XL, Sun S, Xie JT, Aung HH, Tong R, McEntee E, Yuan CS. Methylnaltrexone, a peripherally acting opioid receptor antagonist, enhances tumoricidal effects of 5-Fu on human carcinoma cells. Anticancer Res. 2009;29(8):2927–32 (PMID: 19661297).PubMed

45.

Ma M, Wang X, Liu N, Shan F, Feng Y. Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway. Int Immunopharmacol. 2020;83: 106388. https://doi.org/10.1016/j.intimp.2020.106388 (Epub 2020 Mar 11 PMID: 32171145).CrossRefPubMed

46.

Liu N, Ma M, Qu N, Wang R, Chen H, Hu F, Gao S, Shan F. Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo. Int Immunopharmacol. 2020;86: 106718. https://doi.org/10.1016/j.intimp.2020.106718 (Epub 2020 Jun 22 PMID: 32585612).CrossRefPubMed

47.

Liu N, Yan L, Shan F, Wang X, Qu N, Handley MK, Ma M. Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway. Transl Oncol. 2021;14(4):101028. https://doi.org/10.1016/j.tranon.2021.101028.CrossRefPubMedPubMedCentral

48.

Suzuki M, Chiwaki F, Sawada Y, Ashikawa M, Aoyagi K, Fujita T, Yanagihara K, Komatsu M, Narita M, Suzuki T, Nagase H, Kushima R, Sakamoto H, Fukagawa T, Katai H, Nakagama H, Yoshida T, Uezono Y, Sasaki H. Peripheral opioid antagonist enhances the effect of antitumor drug by blocking a cell growth-suppressive pathway in vivo. PLoS ONE. 2015;10(4): e0123407. https://doi.org/10.1371/journal.pone.0123407.CrossRefPubMedPubMedCentral

49.

McLaughlin PJ, Stucki JK, Zagon IS. Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck. Head Neck. 2012;34(4):513–9. https://doi.org/10.1002/hed.21759 (Epub 2011 May 16 PMID: 21584896).CrossRefPubMed

50.

Zagon IS, McLaughlin PJ. Opioid antagonists inhibit the growth of metastatic murine neuroblastoma. Cancer Lett. 1983;21(1):89–94. https://doi.org/10.1016/0304-3835(83)90087-3 (PMID: 6640516).CrossRefPubMed

51.

Wang X, Zhang R, Wu T, Shi Y, Zhou X, Tang D, Yu W, So EC, Wu X, Pan Z, Tian J. Successive treatment with naltrexone induces epithelial-mesenchymal transition and facilitates the malignant biological behaviors of bladder cancer cells. Acta Biochim Biophys Sin (Shanghai). 2021;53(2):238–48. https://doi.org/10.1093/abbs/gmaa169 (PMID: 33410473).CrossRef

52.

Janku F, Johnson LK, Karp DD, Atkins JT, Singleton PA, Moss J. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol. 2016 Nov;27(11):2032–2038. https://doi.org/10.1093/annonc/mdw317. Epub 2016 Aug 29. Erratum in: Ann Oncol. 2018 Apr 1;29(4):1076. PMID: 27573565; PMCID: PMC6267944. This unplanned post hoc analysis of two randomized trials demonstrates that treatment with MNTX and, even more so, response to MNTX are associated with increased OS, which supports the preclinical hypothesis that MOR can play a role in cancer progression.

53.

Lissoni P, Malugani F, Bordin V, Conti A, Maestroni G, Tancini G. A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone. Neuro Endocrinol Lett. 2002;23(3):255–8 (PMID: 12080288).PubMed

54.

Miskoff JA, Chaudhri M. Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion. Cureus. 2018;10(7): e2924. https://doi.org/10.7759/cureus.2924.PMID:30197847;PMCID:PMC6126779.CrossRefPubMedPubMedCentral

55.

Khan A. Long-term remission of adenoid cystic tongue carcinoma with low dose naltrexone and vitamin D3-a case report. Oral Health Dent Manag. 2014;13(3):721–4 (PMID: 25284545).PubMed

56.

Berkson BM, Rubin DM, Berkson AJ. The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol. Integr Cancer Ther. 2006;5(1):83–9. https://doi.org/10.1177/1534735405285901 (PMID: 16484716).CrossRefPubMed

57.

Berkson BM, Rubin DM, Berkson AJ. Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases. Integr Cancer Ther. 2009;8(4):416–22. https://doi.org/10.1177/1534735409352082.Erratum.In:IntegrCancerTher.2010Jun;9(2):247 (PMID: 20042414).CrossRefPubMed

58.

Berkson BM, Rubin DM, Berkson AJ. Reversal of signs and symptoms of a B-cell lymphoma in a patient using only low-dose naltrexone. Integr Cancer Ther. 2007;6(3):293–6. https://doi.org/10.1177/1534735407306358 (PMID: 17761642).CrossRefPubMed

59.

Berkson BM, Calvo RF. The Long-Term Survival of a Patient With Stage IV Renal Cell Carcinoma Following an Integrative Treatment Approach Including the Intravenous α-Lipoic Acid/Low-Dose Naltrexone Protocol. Integr Cancer Ther. 2018;17(3):986–93. https://doi.org/10.1177/1534735417747984.CrossRefPubMed

60.

Schwartz L, Buhler L, Icard P, Lincet H, Steyaert JM. Metabolic treatment of cancer: intermediate results of a prospective case series. Anticancer Res. 2014;34(2):973–80 (PMID: 24511042).PubMed

Title: Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?
Authors: Amparo Belltall
Guido Mazzinari
Oscar Diaz-Cambronero
Pilar Eroles
María Pilar Argente Navarro
Publication date: 01-06-2022
Publisher: Springer US
Keywords: Naltrexone
Methylnaltrexone
Opioids
Opioids
Published in: Current Oncology Reports / Issue 10/2022
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-022-01295-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 10/2022

Diagnosis and Management of Stroke in Adults with Primary Brain Tumor

Immunological Insights into Opioid-Free Anaesthesia in Oncological Surgery: A Scoping Review

BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner

Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer

Evolving Treatment Approaches to Mucosal Melanoma

What Causes Desmoplastic Reaction in Small Intestinal Neuroendocrine Neoplasms?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer